At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 367 enrolled
Drug / intervention
CT-P17 +1 morebiological
Likely dose
CT-P17 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating CT-P17 and EU-approved Humira for Moderate to Severe Chronic Plaque Psoriasis. Completed, enrolled 367 participants across 1 site.
Detailed Summary
This is a Phase 3 Study to Compare Pharmacokinetics, Efficacy and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEstonia
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartNov 2022
Primary CompletionAug 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedAug 10, 2022
Enrollment StartNov 7, 2022
Primary CompletionAug 14, 2023
Study CompletionFeb 5, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.9 years ago
Interventions
CT-P17biological
CT-P17 40mg will be subcutaneous administered
EU-approved Humirabiological
subcutaneous administration